Advertisement Medtronic gets FDA approval for neurostimulation system - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Medtronic gets FDA approval for neurostimulation system

Medtronic has received FDA approval to market the RestoreULTRA neurostimulation system for the treatment of chronic intractable pain of the trunk and limbs.

The unique patient programmer used with the RestoreULTRA system gives patients more control over their therapy than ever before. In addition, the RestoreULTRA neurostimulator allows patients who use medium stimulation settings to go at least two weeks before needing to recharge. This rechargeable neurostimulator, is claimed to be the most advanced device in the market-leading Medtronic family of RESTORE devices.

Richard Kuntz, senior vice president of Medtronic, and president of the company’s Neuromodulation business, said: “We expect that the innovative features of the RestoreULTRA system will add an important therapy option for patients suffering from chronic pain.”